5-oxo-D-prolinepiperidinamide monohydrate,
NS 105,
NS-105,
Fasoracetam,
110958-19-5,
Fasoracetam [INN],
N-(5-Oxo-D-prolyl)piperidine,
NS 105 (pharmaceutical),
UNII-42O8UF5CJB,
NS-105,
(R)-1-((5-Oxo-2-pyrrolidinyl)carbonyl)piperidine,
42O8UF5CJB,
NCGC00182992-01,
CHEBI:31592,
Piperidine, 1-((5-oxo-2-pyrrolidinyl)carbonyl)-, (R)-,
(R)-5-(piperidine-1-carbonyl)pyrrolidin-2-one,
(5R)-5-(piperidine-1-carbonyl)pyrrolidin-2-one,
(r)-1-[(5-oxo-2-pyrrolidinyl)carbonyl]piperidine,
2-Pyrrolidinone, 5-(1-piperidinylcarbonyl)-, (5R)-,
(+)-1-(((R)-5-Oxo-2-pyrrolidinyl)carbonyl)piperidine,
LAM-105,
AC1L55VI,
DSSTox_CID_28781,
DSSTox_RID_83050,
DSSTox_GSID_48855,
SCHEMBL194770,
CHEMBL2106179,
DTXSID9048855,
EX-A736,
BCP16788,
ZINC3779713,
Tox21_113340,
8126AH,
MFCD00875708,
NS 105,
AKOS006280726,
SB17499,
Fasoracetam ;aka NS-105 ;LAM-105),
LS-115850,
CAS-110958-19-5,
FT-0699901,
C13311,
(5R)-5-(1-piperidinylcarbonyl)-2-pyrrolidinone,
(5R)-5-(piperidine-1-carbonyl) pyrrolidin-2-one,
2-Pyrrolidinone,5-(1-piperidinylcarbonyl)-, (5R)-,
D07WHN,
Fasoracetam < Prop INNM >,
C10H16N2O2,
CID198695,
C10-H16-N2-O2,
5-oxo-d-prolinepiperidinamide Monohydrate,
(R)-5-(Piperidin-1-ylcarbonyl)pyrrolidin-2-one,